Roivant Sciences Ltd (NAS:ROIV)
$ 12.71 0.02 (0.16%) Market Cap: 9.25 Bil Enterprise Value: 3.92 Bil PE Ratio: 2.25 PB Ratio: 1.81 GF Score: 61/100

Roivant Sciences Ltd at Evercore ISI HealthCONx Conference Transcript

Nov 29, 2023 / 05:55PM GMT
Release Date Price: $9.41 (+3.52%)
Unidentified Analyst

Thank you guys for being here. Pleasure to have a management team from Roivant join us. You guys have a lot of cash, what you're planning on doing?

Matthew Gline
Roivant Sciences Ltd. - CEO & Director

We do -- look, post the deal close, we will have roughly $7 billion. I think, look, that's an incredibly privileged place to be. In this interest rate environment, getting over 5% interest on that is not a bad place to be. And the deal hasn't closed. We said it's going to close towards the end of this year or beginning of next year, so don't have it yet. But look, we have -- our burn is roughly, what, 200 a quarter or so. We're spending that on the VTAMA launch and a lot of multiple late-stage clinical programs, we just had fantastic data on 1402 for an Anti-FcRn asset, that can obviously go pretty broad in terms of indications and there's a lot of things out there to be done in terms of deals, right?

I think, look, big pharma is going through a very unique period right now where there's a lot of EPS pressure and there's deals to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot